Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Main billing specialties: urology and urogynecology.
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in the 48 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 107 | 6,731+0.7%/yr | +0.7%/yr | 3.01.3× | 30% | 7,480 in 2030+1.8%/yr |
| Texas | 85 | 6,023−0.4%/yr | −0.4%/yr | 2.81.2× | 24% | 8,340 in 2030+5.6%/yr |
| California | 73 | 5,242+0.1%/yr | +0.1%/yr | 1.60.7× | 20% | 6,070 in 2030+2.5%/yr |
| New York | 38 | 3,138−0.8%/yr | −0.8%/yr | 1.70.8× | 8% | 3,860 in 2030+3.5%/yr |
| Pennsylvania | 45 | 2,928+2.4%/yr | +2.4%/yr | 2.10.9× | 8% | 3,450 in 2030+2.8%/yr |
| Ohio | 37 | 2,896−3.5%/yr | −3.5%/yr | 2.61.2× | 7% | 2,970 in 2030+0.4%/yr |
| Arizona | 38 | 2,602+2%/yr | +2%/yr | 3.51.6× | 38% | 2,760 in 2030+1%/yr |
| Illinois | 39 | 2,574−0.2%/yr | −0.2%/yr | 1.90.8× | 8% | 3,390 in 2030+4.7%/yr |
| Georgia | 34 | 2,423−0.2%/yr | −0.2%/yr | 2.81.2× | 14% | 2,640 in 2030+1.4%/yr |
| Tennessee | 43 | 2,360−3.4%/yr | −3.4%/yr | 3.31.5× | 26% | 2,650 in 2030+1.9%/yr |
| North Carolina | 32 | 2,349−2.5%/yr | −2.5%/yr | 2.41.0× | 5% | 2,230 in 2030−0.8%/yr |
| Virginia | 31 | 2,058−0.5%/yr | −0.5%/yr | 2.00.9× | 11% | 2,110 in 2030+0.4%/yr |
| Massachusetts | 30 | 1,885+3.7%/yr | +3.7%/yr | 2.00.9× | 1% | 2,140 in 2030+2.1%/yr |
| Michigan | 25 | 1,789−6.7%/yr | −6.7%/yr | 2.10.9× | 4% | 1,480 in 2030−3.1%/yr |
| New Jersey | 26 | 1,784−4.1%/yr | −4.1%/yr | 1.70.8× | 9% | 1,880 in 2030+0.9%/yr |
| Indiana | 18 | 1,755−4.5%/yr | −4.5%/yr | 2.51.1× | 16% | 1,650 in 2030−1%/yr |
| South Carolina | 21 | 1,697−2.4%/yr | −2.4%/yr | 2.51.1× | 15% | 2,220 in 2030+4.6%/yr |
| Maryland | 35 | 1,684+0.8%/yr | +0.8%/yr | 1.90.8× | 34% | 1,910 in 2030+2.1%/yr |
| Missouri | 21 | 1,596−2.3%/yr | −2.3%/yr | 2.61.1× | 10% | 1,480 in 2030−1.2%/yr |
| Oklahoma | 26 | 1,344−7%/yr | −7%/yr | 2.81.2× | 10% | 1,310 in 2030−0.5%/yr |
| Washington | 18 | 1,306−6.4%/yr | −6.4%/yr | 1.70.8× | 6% | 1,360 in 2030+0.7%/yr |
| Alabama | 17 | 1,302−0.1%/yr | −0.1%/yr | 2.91.3× | 16% | 1,480 in 2030+2.2%/yr |
| Colorado | 21 | 1,253+1.4%/yr | +1.4%/yr | 2.61.1× | 19% | 1,570 in 2030+3.8%/yr |
| Arkansas | 21 | 1,234−4.1%/yr | −4.1%/yr | 3.21.4× | 30% | 1,060 in 2030−2.6%/yr |
| Minnesota | 16 | 1,110+0.9%/yr | +0.9%/yr | 2.41.1× | 7% | 1,930 in 2030+9.7%/yr |
| Wisconsin | 13 | 1,066+0.3%/yr | +0.3%/yr | 1.90.8× | 3% | 1,370 in 2030+4.2%/yr |
| Kansas | 15 | 1,028−2.4%/yr | −2.4%/yr | 2.51.1× | 21% | 990 in 2030−0.6%/yr |
| Kentucky | 10 | 902−8.4%/yr | −8.4%/yr | 2.00.9× | 11% | 950 in 2030+0.9%/yr |
| Mississippi | 14 | 901−6.8%/yr | −6.8%/yr | 2.41.1× | 45% | 1,040 in 2030+2.4%/yr |
| Oregon | 11 | 883−0.6%/yr | −0.6%/yr | 2.10.9× | 21% | 1,300 in 2030+6.6%/yr |
| Louisiana | 10 | 866−4%/yr | −4%/yr | 2.10.9× | 3% | 710 in 2030−3.3%/yr |
| Nebraska | 12 | 849−2%/yr | −2%/yr | 3.21.4× | 24% | 1,020 in 2030+3.1%/yr |
| Connecticut | 11 | 668+0.3%/yr | +0.3%/yr | 2.00.9× | 0% | 740 in 2030+1.6%/yr |
| Nevada | 8 | 631−0.3%/yr | −0.3%/yr | 2.21.0× | 19% | 1,080 in 2030+9.3%/yr |
| Iowa | 7 | 604−0.6%/yr | −0.6%/yr | 1.40.6× | 14% | 600 in 2030−0.1%/yr |
| Utah | 6 | 487−2.4%/yr | −2.4%/yr | 2.21.0× | 7% | 610 in 2030+3.9%/yr |
| South Dakota | 4 | 4160%/yr | 0%/yr | 3.21.4× | 0% | 540 in 2030+4.4%/yr |
| Idaho | 4 | 408+1.3%/yr | +1.3%/yr | 2.00.9× | 11% | 900 in 2030+14%/yr |
| Montana | 6 | 361+0.1%/yr | +0.1%/yr | 1.90.8× | 0% | 370 in 2030+0.3%/yr |
| New Hampshire | 5 | 344−2.3%/yr | −2.3%/yr | 1.50.7× | 0% | 460 in 2030+4.9%/yr |
| West Virginia | 6 | 311−5%/yr | −5%/yr | 1.50.7× | 0% | 360 in 2030+2.4%/yr |
| District of Columbia | 4 | 288+6.1%/yr | +6.1%/yr | 4.62.0× | 13% | 350 in 2030+3.4%/yr |
| Delaware | 3 | 284−1.8%/yr | −1.8%/yr | 1.60.7× | 0% | 370 in 2030+4.5%/yr |
| Rhode Island | 2 | 201+0.4%/yr | +0.4%/yr | 2.21.0× | 31% | 130 in 2030−7.5%/yr |
| New Mexico | 2 | 167−7.1%/yr | −7.1%/yr | 0.70.3× | 9% | 240 in 2030+6.5%/yr |
| Hawaii | 4 | 114−4.8%/yr | −4.8%/yr | 0.90.4× | 0% | 260 in 2030+15%/yr |
| Alaska | 2 | 107−0.7%/yr | −0.7%/yr | 0.90.4× | 0% | 90 in 2030−2.7%/yr |
| Maine | 2 | 101−14%/yr | −14%/yr | 0.60.3× | 0% | 40 in 2030−13%/yr |
Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 416 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 11 companies. The most active:
Product codes: EZW (stimulator, electrical, implantable, for incontinence), EZY (device, incontinence, mechanical/hydraulic), FAE (prosthesis, penile), FAG (prosthesis, urethral sphincter), OTN (mesh, surgical, synthetic, urogynecologic, for stress urinary incontinence, retropubic or transobturator), OTO (mesh, surgical, synthetic, urogynecologic, for apical vaginal and uterine prolapse, transabdominally placed), OTP (mesh, surgical, synthetic, urogynecologic, for pelvic organ prolapse, transvaginally placed), PAI (mesh, surgical, non-synthetic, urogynecologic, for pelvic organ prolapse, transvaginally placed), PAJ (mesh, surgical, non-synthetic, urogynecologic, for apical vaginal and uterine prolapse, transabdominally placed). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +6 pts since 2019, to 17%.
The 10 busiest do 30% of the cases CMS names in Florida; 57 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Kidney stone management | 3,401 | 159,938−1.4%/yr | −1.4%/yr | 172,300 in 2030+1.2%/yr |
| BPH procedures | 2,196 | 155,142−6.4%/yr | −6.4%/yr | 148,000 in 2030−0.8%/yr |
| Hysterectomy, hysteroscopy & ablation | 906 | 83,637−1.3%/yr | −1.3%/yr | 95,100 in 2030+2.2%/yr |
| Prostatectomy & nephrectomy | 592 | 37,032−1.1%/yr | −1.1%/yr | 45,600 in 2030+3.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 19 companies reported engagement with surgeons in the covered states worth $11M in consulting, speaking, meals and travel tied to these products, about $10K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.